Week in Review: BVCF Seeking $400 Million for Fourth China Life Science Fund

BVCF (BioVeda China Fund), a Shanghai-based life science fund, is raising $400 million in its fourth US dollar fund, with a final close expected before the end of 2016; BGI of Shenzhen is planning a $600 million IPO on the ChiNext Exchange for its BGI Dx and BGI Tech subsidiaries; Beijing's Phoenix Healthcare Group will acquire the hospital operations of China Resources Healthcare for $480 million of stock; WuXi AppTec acquired Crelux of Munich, Germany, a structure-based protein drug discovery company; Singapore's NMT Pharma in-licensed worldwide rights to a cancer drug co-developed by itself and CAO Pharma of Houston, Texas; DiaCarta, a US-China molecular cancer diagnostics company, obtained US-China rights to a liquid biopsy test developed by Spain's Pangaea Biotech; BioSciKin, a China life science incubator, completed the first two preliminary contests in a US-China competition for novel startups; Hutchison China MediTech began a first-in-human Phase I clinical trial of novel cancer drug in Australia; and a panel at the BIO-Europe Spring 2016 conference declared unequivocally that "China biotech cross-border dealmaking is hot." Stock Symbols: (HK: 1515) (NSDQ/AIM: HCM) Share this with colleagues: // //